SENS PubMed Publication Search
Celastrol, a TFEB (transcription factor EB) agonist, is a promising drug candidate for Alzheimer disease
Autophagy. 2022 Mar 6;1-3. doi: 10.1080/15548627.2022.2046437.
Wei Zhang 1 2, Jigang Wang 1 3 4 5, Chuanbin Yang 1
Abstract:
...In a recent study, we showed that celastrol, a natural small molecule with an anti-obesity effect, is a novel TFEB activator, which enhances autophagy and lysosomal biogenesis both in vitro and in animal brains. Consequently, celastrol promotes the degradation of phosphorylated MAPT/tau aggregates both in cells and in the brain of P301S MAPT/tau and 3XTg mice, two commonly used AD animal models. Interestingly, celastrol also alleviates memory deficits in these mice. Altogether, celastrol enhances TFEB-mediated autophagy and lysosomal biogenesis to ameliorate MAPT/tau pathology, suggesting that celastrol represents a novel anti-AD and other tauopathies drug candidate.
PMID: 35253615
Tags: 3xTg, Alzheimer’s, animal models, autophagy, Celastrol, mice, P301S, TFEB